171 related articles for article (PubMed ID: 22347800)
1. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.
Gandhi SK; Jensen MM; Fox KM; Smolen L; Olsson AG; Paulsson T
Clinicoecon Outcomes Res; 2012; 4():1-11. PubMed ID: 22347800
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Wagner M; Lindgren P; Merikle E; Goetghebeur M; Jönsson B
Can J Cardiol; 2009 Nov; 25(11):e362-9. PubMed ID: 19898698
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
8. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
Ara R; Pandor A; Stevens J; Rees A; Rafia R
Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia.
Mould-Quevedo JF; Gutiérrez-Ardila MV; Ordóñez Molina JE; Pinsky B; Vargas Zea N
Value Health Reg Issues; 2014 Dec; 5():48-57. PubMed ID: 29702787
[TBL] [Abstract][Full Text] [Related]
15. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
17. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
18. Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
Straka RJ; Mamdani M; Damen J; Kuntze CE; Liu LZ; Botteman MF; Koren MJ
Curr Med Res Opin; 2007 Jul; 23(7):1517-29. PubMed ID: 17535539
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.
Fragoulakis V; Kourlaba G; Maniadakis N
Clinicoecon Outcomes Res; 2012; 4():135-43. PubMed ID: 22719213
[TBL] [Abstract][Full Text] [Related]
20. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland.
Soini EJ; Davies G; Martikainen JA; Hu HX; Tunceli K; Niskanen L
Curr Med Res Opin; 2010 Jan; 26(1):25-36. PubMed ID: 19895364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
